Holen Sie sich die Stockscreener-App
82.33
1.25%
-1.04
Schlusskurs vom Vortag:
$83.37
Offen:
$83.81
24-Stunden-Volumen:
2.08M
Relative Volume:
0.88
Marktkapitalisierung:
$15.93B
Einnahmen:
$8.41B
Nettoeinkommen (Verlust:
$760.80M
KGV:
21.38
EPS:
3.8513
Netto-Cashflow:
$1.05B
1W Leistung:
-0.69%
1M Leistung:
-11.48%
6M Leistung:
-6.97%
1J Leistung:
-13.44%
1-Tages-Spanne:
$82.04
$83.99
1-Wochen-Bereich:
$82.04
$84.50
52-Wochen-Spanne:
$79.83
$108.29
Zimmer Biomet Holdings Inc Stock (ZBH) Company Profile
Firmenname
Zimmer Biomet Holdings Inc
Sektor
Branche
Telefon
(574) 267-6131
Adresse
345 EAST MAIN STREET, WARSAW, IN
Compare ZBH vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZBH
Zimmer Biomet Holdings Inc
|
82.33 | 15.93B | 8.41B | 760.80M | 1.05B | 3.8513 |
ABT
Abbott Laboratories
|
84.32 | 146.87B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
285.47 | 109.33B | 25.27B | 3.34B | 4.57B | 8.6358 |
MDT
Medtronic Plc
|
76.15 | 97.77B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
53.93 | 80.16B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
79.96 | 46.04B | 6.30B | 1.07B | 1.34B | 1.8406 |
Zimmer Biomet Holdings Inc Stock (ZBH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-23 | Herabstufung | BTIG Research | Buy → Neutral |
| 2026-02-20 | Eingeleitet | William Blair | Mkt Perform |
| 2026-01-09 | Herabstufung | Goldman | Neutral → Sell |
| 2026-01-06 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2026-01-05 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-12-16 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2025-11-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-09-18 | Eingeleitet | Rothschild & Co Redburn | Buy |
| 2025-07-15 | Hochstufung | Roth Capital | Neutral → Buy |
| 2024-12-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-09-10 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-07-01 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-05-30 | Eingeleitet | Goldman | Neutral |
| 2024-05-21 | Hochstufung | Argus | Hold → Buy |
| 2024-01-04 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-10-20 | Eingeleitet | ROTH MKM | Neutral |
| 2023-08-28 | Hochstufung | BTIG Research | Neutral → Buy |
| 2023-05-03 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-04-11 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-03-31 | Hochstufung | Jefferies | Underperform → Hold |
| 2023-03-29 | Eingeleitet | UBS | Sell |
| 2023-03-10 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-01-09 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-01-05 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-01-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-11-23 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2022-10-18 | Eingeleitet | Barclays | Underweight |
| 2022-10-12 | Eingeleitet | Jefferies | Underperform |
| 2022-05-27 | Herabstufung | Needham | Buy → Hold |
| 2022-04-13 | Herabstufung | Truist | Buy → Hold |
| 2022-04-01 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-03-02 | Fortgesetzt | BofA Securities | Underperform |
| 2022-03-02 | Herabstufung | Loop Capital | Buy → Hold |
| 2022-02-08 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-02-08 | Bestätigt | Citigroup | Buy |
| 2022-02-08 | Bestätigt | Deutsche Bank | Hold |
| 2022-02-08 | Bestätigt | JMP Securities | Mkt Outperform |
| 2022-02-08 | Bestätigt | JP Morgan | Neutral |
| 2022-02-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2022-02-08 | Bestätigt | Stifel | Buy |
| 2022-02-08 | Bestätigt | Truist | Buy |
| 2022-02-08 | Bestätigt | UBS | Neutral |
| 2022-02-08 | Bestätigt | Wells Fargo | Underweight |
| 2022-02-02 | Herabstufung | UBS | Buy → Neutral |
| 2022-01-19 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2022-01-10 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-01-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-01-04 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-12-09 | Herabstufung | Needham | Strong Buy → Buy |
| 2021-12-07 | Eingeleitet | Loop Capital | Buy |
| 2021-11-23 | Herabstufung | Argus | Buy → Hold |
| 2021-09-14 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-09 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2021-01-04 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-12-18 | Bestätigt | Needham | Strong Buy |
| 2020-10-20 | Eingeleitet | Northland Capital | Market Perform |
| 2020-09-11 | Eingeleitet | Wolfe Research | Outperform |
| 2020-08-05 | Bestätigt | Needham | Strong Buy |
| 2020-04-28 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-04-09 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2020-04-07 | Bestätigt | Needham | Strong Buy |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Buy |
| 2020-01-08 | Eingeleitet | SunTrust | Buy |
| 2020-01-07 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2020-01-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2019-12-04 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2019-10-07 | Hochstufung | BTIG Research | Neutral → Buy |
| 2019-09-18 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-08-12 | Hochstufung | Argus | Hold → Buy |
| 2019-07-30 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2019-07-29 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2019-06-11 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2019-04-24 | Hochstufung | Needham | Buy → Strong Buy |
Alle ansehen
Zimmer Biomet Holdings Inc Aktie (ZBH) Neueste Nachrichten
Zimmer Biomet (NYSE:ZBH) Rating Increased to Buy at Wall Street Zen - MarketBeat
Zimmer Biomet Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch
Oak Family Advisors LLC Sells 37,733 Shares of Zimmer Biomet Holdings, Inc. $ZBH - MarketBeat
Zimmer Biomet to Present at the BofA Securities 2026 Health Care Conference - PR Newswire
Zimmer Biomet (ZBH) CAO awarded 9,232 RSUs vesting over three years - Stock Titan
How Zimmer Biomet Holdings Inc. (ZBH) Affects Rotational Strategy Timing - Stock Traders Daily
Why Zimmer Biomet (ZBH) is a Top Growth Stock for the Long-Term - Yahoo Finance
Zimmer Biomet (ZBH) Is Down 9.2% After Strong Q1, CFO Exit And Ongoing Buybacks – Has The Bull Case Changed? - Sahm
Robertson Stephens Wealth Management LLC Buys Shares of 12,539 Zimmer Biomet Holdings, Inc. $ZBH - MarketBeat
Zimmer Biomet Holdings, Inc. (ZBH) Stock Analysis: Navigating A Potential 18.85% Upside - DirectorsTalk Interviews
Zimmer Biomet Announces Chief Financial Officer Transition - Building Indiana Business
BofA Securities Maintains Zimmer Biomet Holdings(ZBH.US) With Hold Rating, Maintains Target Price $100 - Moomoo
Zimmer Biomet Holdings 1Q 2026: Revenue $2.09B, EPS $1.22— 10-Q Summary - TradingView
Zimmer Biomet (NYSE: ZBH) posts Q1 2026 growth and updates 2026 view - Stock Titan
Zimmer Biomet Ordered to Defend Fraud Claim in Device Deal Case - Bloomberg Law News
Zimmer Biomet Announces Webcast and Conference Call of First Quarter 2026 Financial Results - Quantisnow
Here's Why Zimmer Biomet (ZBH) is a Strong Value Stock - Yahoo Finance
Results: Zimmer Biomet Holdings, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts - simplywall.st
Zimmer Biomet Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Vanguard holds 7.54% of Zimmer Biomet (ZBH) via Schedule 13G filing - Stock Titan
Zimmer Biomet falls after CEO exit, unchanged growth outlook - MSN
Zimmer Biomet Stock (US98956P1021): Q3 2025 Earnings Beat Expectations with 5.2% Revenue Growth - AD HOC NEWS
A Look At Zimmer Biomet (ZBH) Valuation After CFO Exit And Solid Quarterly Results - Yahoo Finance
A Quick Look at Today's Ratings for Zimmer Biomet Holdings(ZBH.US), With a Forecast Between $83 to $105 - Moomoo
Zimmer Biomet Holdings (ZBH) Receives a Hold from Truist Financial - The Globe and Mail
RBC Capital Sticks to Their Buy Rating for Zimmer Biomet Holdings (ZBH) - The Globe and Mail
Vanguard Group Inc. Buys 192,517 Shares of Zimmer Biomet Holdings, Inc. $ZBH - MarketBeat
Zimmer Biomet Holdings Hits New 52-Week Low at $81.36 - Markets Mojo
Zimmer Biomet Buzz Grows Across NYSE Composite Trend - Kalkine Media
Zimmer Biomet Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Zimmer Biomet (NYSE:ZBH) Given New $95.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Zimmer Biomet Q1 2026 earnings preview - MSN
Zimmer Biomet Supported by Sales Force Improvements, 2026 Upside Potential, RBC Says - marketscreener.com
Zimmer Biomet (NYSE:ZBH) Price Target Cut to $105.00 by Analysts at Citizens Jmp - MarketBeat
Zimmer Biomet CFO Suketu Upadhyay to depart - MSN
Wells Fargo & Company Lowers Zimmer Biomet (NYSE:ZBH) Price Target to $90.00 - MarketBeat
Zimmer Biomet (NYSE:ZBH) Price Target Lowered to $105.00 at Stifel Nicolaus - MarketBeat
Zimmer Biomet's (ZBH) Hold Rating Reaffirmed at Truist Financial - MarketBeat
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Q1 2026 Earnings Call Transcript - Insider Monkey
JPMorgan Adjusts Price Target on Zimmer Biomet Holdings to $95 From $100, Maintains Neutral Rating - marketscreener.com
Citigroup Adjusts Price Target on Zimmer Biomet to $95 From $98, Maintains Neutral Rating - marketscreener.com
Baird Adjusts Price Target on Zimmer Biomet to $92 From $100, Maintains Neutral Rating - marketscreener.com
Zimmer Biomet net sales up 9.3% to USD 2.087B in Q1 2026 - Medical Buyer
Barclays Adjusts Price Target on Zimmer Biomet to $94 From $100, Maintains Underweight Rating - marketscreener.com
Goldman Sachs Adjusts Price Target on Zimmer Biomet to $86 From $89, Maintains Sell Rating - marketscreener.com
Wells Fargo Adjusts Price Target on Zimmer Biomet to $90 From $98, Maintains Equalweight Rating - marketscreener.com
Stifel Adjusts Price Target on Zimmer Biomet to $105 From $110, Maintains Buy Rating - marketscreener.com
Citizens cuts Zimmer Biomet stock price target on mixed results By Investing.com - Investing.com South Africa
Zimmer Biomet (NYSE:ZBH) Hits New 12-Month LowShould You Sell? - MarketBeat
Citizens cuts Zimmer Biomet stock price target on mixed results - Investing.com
Zimmer Biomet Holdings Inc (ZBH) Q1 2026 Earnings Call Highlights: Strong Start with 9.3% Revenue Growth - GuruFocus
Finanzdaten der Zimmer Biomet Holdings Inc-Aktie (ZBH)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.92%
0.18%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):